Briacell Therap (NASDAQ:BCTX) Short Interest Down 19.7% in April

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totaling 227,052 shares, a drop of 19.7% from the March 31st total of 282,815 shares. Based on an average daily volume of 120,174 shares, the short-interest ratio is currently 1.9 days. Approximately 3.2% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new position in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent quarter. 15.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Briacell Therap Stock Performance

Shares of NASDAQ BCTX remained flat at $4.18 during midday trading on Friday. 102,163 shares of the company’s stock were exchanged, compared to its average volume of 406,049. The company’s 50-day moving average is $4.12 and its 200-day moving average is $6.83. The company has a market cap of $30.31 million, a PE ratio of -0.18 and a beta of 1.30. Briacell Therap has a fifty-two week low of $3.60 and a fifty-two week high of $41.30.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.